Combination Therapy May Increase Lesion Closure in PCV - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Combination Therapy May Increase Lesion Closure in PCV

The combination of photodynamic therapy and intravitreal  aflibercept did not improve 1-year visual acuity outcomes compared with aflibercept monotherapy.

  • By

  • Andrea Surnit

  • May 13, 2026

  • 3 min

Share

  • 1

    Combination therapy with reduced-fluence photodynamic therapy and aflibercept did not improve visual acuity compared to aflibercept alone.

  • 2

    The study showed higher early polypoidal lesion closure rates with combination therapy at week 12 compared to monotherapy.

  • 3

    At week 52, lesion closure rates were 73% for combination therapy versus 47% for monotherapy.

  • 4

    No serious adverse events were reported in either treatment group during the trial.

  • 5

    The study faced limitations due to a smaller sample size and delays, impacting the ability to draw definitive conclusions.

Original Source(s)

Combination Therapy May Increase Lesion Closure in PCV

  • by Andrea Surnit

  • May 13, 2026

Related Content

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Diagnosing and Managing Polypoidal Choroidal Vasculopathy

Polypoidal choroidal vasculopathy (PCV) is a distinct choroidal vascular disorder often considered a variant of age-related macular degeneration (AMD), although features such as drusen, pigmentary changes, and geographic atrophy are uncommon.

Highlights From Atlantic Coast Retina Club and Macula 2026